Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 13/20 | 0.76 |
| ▸ | KDR | P35968 | 13/20 | 0.76 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.62 |
| ▸ | TP53 | P04637 | 2/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.62 |
| ▸ | GOT1 | P17174 | 2/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.62 |
| ▸ | NPC1 | O15118 | 2/20 | 0.62 |
| ▸ | RAB9A | P51151 | 2/20 | 0.62 |
| ▸ | MPO | P05164 | 2/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.62 |
| ▸ | LMNA | P02545 | 2/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.62 |
| ▸ | PKM | P14618 | 1/20 | 0.62 |
| ▸ | MAOA | P21397 | 1/20 | 0.62 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.62 |
| ▸ | THPO | P40225 | 1/20 | 0.62 |
| ▸ | AOX1 | Q06278 | 1/20 | 0.62 |
| ▸ | ACOX1 | Q15067 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31426459 | 1.00 | EGFR (0.76) | EGFRKDRKDM4ETP53CYP3A4 | |
| SCHEMBL13286756 | 0.88 | NPC1 (0.71) | EGFRKDRKDM4ETP53CYP3A4 | |
| SCHEMBL3759264 | 0.88 | EGFR (0.74) | EGFRKDRKDM4ETP53CYP3A4 | |
| SCHEMBL6606282 | 0.86 | KDR (0.72) | EGFRKDRKDM4ETP53CYP3A4 | |
| SCHEMBL10356806 | 0.86 | EGFR (0.72) | EGFRKDRKDM4ETP53CYP3A4 | |
| SCHEMBL4783313 | 0.82 | EGFR (0.58) | EGFRKDRKDM4ETP53CYP3A4 | |
| SCHEMBL4820797 | 0.82 | SMN1; SMN2 (0.59) | EGFRKDRKDM4ETP53CYP3A4 | |
| SCHEMBL3768687 | 0.81 | EGFR (0.71) | EGFRKDRKDM4ETP53CYP3A4 | |
| SCHEMBL14283135 | 0.80 | EGFR (0.52) | EGFRKDRKDM4ETP53CYP3A4 | |
| SCHEMBL14283138 | 0.80 | EGFR (0.52) | EGFRKDRKDM4ETP53CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 142 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2708556-B1 | PHARMACEUTICAL COMPOSITION FOR THE USE IN A COMBINATION THERAPY FOR PREVENTION OR TREATMENT OF C-MET OR ANGIOGENESIS FACTOR INDUCED DISEASES | SAMSUNG ELECTRONICS CO LTD (KR) | 2018-11-07 | — | — | EP | claimed |
| US-9931400-B2 | Method of combination therapy for prevention or treatment of c-Met or angiogenesis factor induced diseases | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2018-04-03 | — | — | US | claimed |
| US-20140086926-A1 | METHOD OF COMBINATION THERAPY FOR PREVENTION OR TREATMENT OF C-MET OR ANGIOGENESIS FACTOR INDUCED DISEASES | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2014-03-27 | — | — | US | claimed |
| EP-2708556-A1 | Pharmaceutical composition for the use in a combination therapy for prevention or treatment of C-Met or angiogenesis factor induced diseases | Samsung Electronics Co., Ltd (KR) | 2014-03-19 | — | — | EP | claimed |
| EP-4743106-A1 | METHODS OF USING THE BRAIN-DERIVED OSTEOGENIC FACTOR CCN3 FOR TREATMENT OF BONE AND CARTILAGE DEGENERATION | The Regents of University of California (US) | 2026-05-20 | — | — | EP | disclosed |
| WO-2025101807-A1 | TREATMENT OF GLIOMAS WITH CHIMERIC ANTIGEN RECEPTOR T CELLS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2025-05-15 | — | — | WO | disclosed |
| US-12295939-B2 | Substituted benzothiophene analogs as selective estrogen receptor degraders | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2025-05-13 | — | — | US | disclosed |
| US-20250074981-A1 | COMBINATION THERAPY WITH DEXAMETHASONE AND TUMOR-SPECIFIC T CELL ENGAGING MULTI-SPECIFIC ANTIBODIES FOR TREATING CANCER | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2025-03-06 | — | — | US | disclosed |
| WO-2025049342-A1 | METHODS OF USING THE BRAIN-DERIVED OSTEOGENIC FACTOR CCN3 FOR TREATMENT OF BONE AND CARTILAGE DEGENERATION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-03-06 | — | — | WO | disclosed |
| US-20240270854-A1 | ENGINEERED BMP2 SURROGATE PROTEINS | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2024-08-15 | — | — | US | disclosed |
| US-20240181135-A1 | BIOCHEMICAL ACTIVATION OF DYSFUNCTIONAL SKELETAL STEM CELLS FOR SKELETAL REGENERATION | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | 2024-06-06 | — | — | US | disclosed |
| US-20240174764-A1 | METHODS FOR TREATING GYNECOLOGIC CANCER USING COMBINATION THERAPY WITH ANTI-MUC16 x CD3 MULTISPECIFIC ANTIBODIES AND VEGF INHIBITORS | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2024-05-30 | — | — | US | disclosed |
| WO-2005097121-A1 | ANGIOGENESIS-AFFECTING COMPOUNDS AND METHODS OF USE THEREOF | ANGIOGENETICS SWEDEN AB (SE) | 2005-10-20 | — | — | WO | disclosed |
| US-20050020583-A1 | Amino-phthalazinone derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them | PFIZER ITALIA S.R.L. (IT) | 2005-01-27 | — | — | US | disclosed |
| EP-1427708-A1 | AMINO-PHTHALAZINONE DERIVATIVES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Pharmacia Italia S.p.A. (IT) | 2004-06-16 | — | — | EP | disclosed |
| US-20030073692-A1 | Amino-phthalazinone derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them | PHARMACIA & UPJOHN S.P.A. (IT) | 2003-04-17 | — | — | US | disclosed |
| WO-2003014090-A1 | AMINO-PHTHALAZINONE DERIVATIVES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | PHARMACIA ITALIA S.P.A. (IT) | 2003-02-20 | — | — | WO | disclosed |
| EP-0975605-A1 | PYRIDAZINE AND PHTHALAZINE DERIVATIVES, PROCESS OF THEIR PREPARATION AND THEIR USE AS ANTICONVULSANTS | SMITHKLINE BEECHAM PLC (GB) | 2000-02-02 | — | — | EP | disclosed |
| WO-1998046574-A1 | PYRIDAZINE AND PHTHALAZINE DERIVATIVES, PROCESS OF THEIR PREPARATION AND THEIR USE AS ANTICONVULSANTS | SMITHKLINE BEECHAM PLC (GB) | 1998-10-22 | — | — | WO | disclosed |
| US-5438064-A | For suppressing the binding of bradykinins to pain receptors | AMERICAN HOME PRODUCTS CORPORATION (US) | 1995-08-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12295939-B2 | Substituted benzothiophene analogs as selective estrogen receptor degraders | ESR1, GPER1, CYP19A1 | EGFR 19/4885KDR 527/4885KDM4E 304/4885 |
| US-20030073692-A1 | Amino-phthalazinone derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them | MAP3K20, MAP3K15, MAP3K5 | EGFR 1055/4885KDR 2165/4885KDM4E 779/4885 |
| US-20240270854-A1 | ENGINEERED BMP2 SURROGATE PROTEINS | BMP2, BMPR1A, BMPR2 | EGFR 605/4885KDR 255/4885KDM4E 3847/4885 |
| US-20050020583-A1 | Amino-phthalazinone derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them | MAP3K20, MAP3K1, MAP3K15 | EGFR 664/4885KDR 1929/4885KDM4E 710/4885 |
| US-20240174764-A1 | METHODS FOR TREATING GYNECOLOGIC CANCER USING COMBINATION THERAPY WITH ANTI-MUC16 x CD3 MULTISPECIFIC ANTIBODIES AND VEGF INHIBITORS | MUC1, CD4, CD2 | EGFR 64/4885KDR 13/4885KDM4E 3415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.